Literature DB >> 16792673

The association of CTLA-4 and HLA class II autoimmune risk genotype with regulatory T cell marker expression in 5-year-old children.

C-O Jonson1, M Hedman, M Karlsson Faresjö, R Casas, J Ilonen, J Ludvigsson, O Vaarala.   

Abstract

Regulatory T cells (Treg) are involved in the maintenance of peripheral tolerance by suppression of autoreactive lymphocytes that have avoided thymic depletion. The defective function of Treg cells has recently attracted attention in autoimmune diseases such as type 1 diabetes (T1D), rheumatoid arthritis and multiple sclerosis. Susceptibility to these diseases is associated with specific human leucocyte antigen (HLA) class II and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) gene polymorphisms. This study aimed to investigate the relationship between HLA class II and CTLA +49 A/G polymorphisms associated with susceptibility to T1D and the number and characteristics of Treg cells in children. Samples from 47 5-year-old children who participated in the All Babies in South-east Sweden (ABIS) follow-up study were grouped according to the presence of the T1D risk-associated HLA genotype (DQA1*0501-DQB1*0201, DQA1*0301-DQB1*0302) or neutral HLA genotypes. Lower percentages of CD4+ T cells (P = 0.03) and CD4+ CD25high cells (P = 0.06) expressing intracellular CTLA-4 were detected in samples from children with CTLA-4 +49GG compared to children with the +49AA genotype. Similarly, lower percentages of CD4+ (P = 0.002) and CD4+ CD25high (P = 0.002) cells expressing CTLA-4 were observed in children positive for HLA DQA1*0501-DQB1*0201 and DQA1*0301-DQB1*0302 (P = 0.04 for CD4+ and P = 0.02 for CD4+ CD25high) risk haplotypes when compared to children without these alleles. The percentage of CD25high cells among CD4+ cells was correlated inversely with CTLA-4 mRNA expression in PBMC (r = -0.56, P = 0.03). Decreased levels of CTLA-4 in CD4+ and CD4+ CD25high cells in individuals with CTLA-4 and HLA class II alleles associated with T1D may contribute to the initiation and/or progression of autoimmune response.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16792673      PMCID: PMC1942013          DOI: 10.1111/j.1365-2249.2006.03106.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  47 in total

1.  Association of CTLA4 polymorphism with regulatory T cell frequency.

Authors:  Sowsan F Atabani; Chloe L Thio; Senad Divanovic; Aurelien Trompette; Yasmine Belkaid; David L Thomas; Christopher L Karp
Journal:  Eur J Immunol       Date:  2005-07       Impact factor: 5.532

2.  Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes.

Authors:  Shelley Lindley; Colin M Dayan; Amanda Bishop; Bart O Roep; Mark Peakman; Timothy I M Tree
Journal:  Diabetes       Date:  2005-01       Impact factor: 9.461

3.  Fas-independent death of activated CD4(+) T lymphocytes induced by CTLA-4 crosslinking.

Authors:  P Scheipers; H Reiser
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

Review 4.  Is CTLA-4 a master switch for peripheral T cell tolerance?

Authors:  J A Bluestone
Journal:  J Immunol       Date:  1997-03-01       Impact factor: 5.422

5.  HLA class II-associated polymorphism of interferon-gamma production. Implications for HLA-disease association.

Authors:  N Petrovsky; L C Harrison
Journal:  Hum Immunol       Date:  1997-03       Impact factor: 2.850

6.  CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice.

Authors:  E A Tivol; S D Boyd; S McKeon; F Borriello; P Nickerson; T B Strom; A H Sharpe
Journal:  J Immunol       Date:  1997-06-01       Impact factor: 5.422

7.  Allelic effects on gene regulation at the autoimmunity-predisposing CTLA4 locus: a re-evaluation of the 3' +6230G>A polymorphism.

Authors:  S M Anjos; W Shao; L Marchand; C Polychronakos
Journal:  Genes Immun       Date:  2005-06       Impact factor: 2.676

8.  Regulation of CTLA-4 expression during T cell activation.

Authors:  D Perkins; Z Wang; C Donovan; H He; D Mark; G Guan; Y Wang; T Walunas; J Bluestone; J Listman; P W Finn
Journal:  J Immunol       Date:  1996-06-01       Impact factor: 5.422

9.  Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation.

Authors:  M Asano; M Toda; N Sakaguchi; S Sakaguchi
Journal:  J Exp Med       Date:  1996-08-01       Impact factor: 14.307

10.  CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production.

Authors:  A M Thornton; E M Shevach
Journal:  J Exp Med       Date:  1998-07-20       Impact factor: 14.307

View more
  6 in total

1.  IFN-gamma and IL-10 islet-antigen-specific T cell responses in autoantibody-negative first-degree relatives of patients with type 1 diabetes.

Authors:  L G Petrich de Marquesini; J Fu; K J Connor; A J Bishop; N E McLintock; C Pope; F S Wong; C M Dayan
Journal:  Diabetologia       Date:  2010-04-06       Impact factor: 10.122

2.  CTLA-4 exon 1 +49 polymorphism alone and in a haplotype with -318 promoter polymorphism may confer susceptibility to chronic HBV infection in Chinese Han patients.

Authors:  Shaoqiong Duan; Guoyu Zhang; Qunying Han; Zhu Li; Zhengwen Liu; Jinghong Chen; Yi Lv; Na Li; Yawen Wang; Man Li; Sai Lou; Mingbo Yang; Qianqian Zhu; Fanfan Xing
Journal:  Mol Biol Rep       Date:  2010-12-15       Impact factor: 2.316

Review 3.  The role of regulatory T cells and genes involved in their differentiation in pathogenesis of selected inflammatory and neoplastic skin diseases. Part III: Polymorphisms of genes involved in Tregs' activation and function.

Authors:  Bogusław Nedoszytko; Małgorzata Sokołowska-Wojdyło; Joanna Renke; Magdalena Lange; Piotr Trzonkowski; Michał Sobjanek; Aneta Szczerkowska-Dobosz; Marek Niedoszytko; Aleksandra Górska; Jan Romantowski; Jarosław Skokowski; Leszek Kalinowski; Roman J Nowicki
Journal:  Postepy Dermatol Alergol       Date:  2017-12-31       Impact factor: 1.837

4.  CTLA-4 +49 G/A, a functional T1D risk SNP, affects CTLA-4 level in Treg subsets and IA-2A positivity, but not beta-cell function.

Authors:  Yang Chen; Shu Chen; Yong Gu; Yingjie Feng; Yun Shi; Qi Fu; Zhixiao Wang; Yun Cai; Hao Dai; Shuai Zheng; Min Sun; Mei Zhang; Xinyu Xu; Heng Chen; Kuanfeng Xu; Tao Yang
Journal:  Sci Rep       Date:  2018-07-04       Impact factor: 4.379

5.  Impact of Single-Nucleotide Polymorphisms of CTLA-4, CD80 and CD86 on the Effectiveness of Abatacept in Patients with Rheumatoid Arthritis.

Authors:  Noelia Marquez Pete; María Del Mar Maldonado Montoro; Cristina Pérez Ramírez; Almudena Sánchez Martín; Juan Enrique Martínez de la Plata; Fernando Martínez Martínez; Rafael Caliz Caliz; Abdelali Daddaoua; María Del Carmen Ramírez Tortosa; Alberto Jiménez Morales
Journal:  J Pers Med       Date:  2020-11-11

6.  Analysis of DLA-DQB1 and polymorphisms in CTLA4 in Cocker spaniels affected with immune-mediated haemolytic anaemia.

Authors:  Anna J Threlfall; Alisdair M Boag; Francesca Soutter; Barbara Glanemann; Harriet M Syme; Brian Catchpole
Journal:  Canine Genet Epidemiol       Date:  2015-06-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.